Role of the proto-oncogene Pokemon in cellular transformation and ARF repression

Nature

Volumn 433, Issue 7023, 2005, Pages 278-285

  Maeda, Takahiro ^a   Hobbs, Robin H ^a   Morghoub, Taha ^a   Guernah, Ilhem ^a   Zelent, Arthur ^b   Cordon Cardo, Carlos ^a   Teruya Feldstein, Julle ^a   Pandolfi, Pler Paolo ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; ENZYMES; GENES; MOLECULAR STRUCTURE; TUMORS;

CELLULAR TRANSFORMATION; CHROMATIN; ONCOGENESIS; PROTO-ONCOGENE POKEMON; TRANSCRIPTIONAL REPRESSION; TRANSGENIC MICE;

CELLS;

ARF PROTEIN; HISTONE; HISTONE DEACETYLASE INHIBITOR;

TUMOR;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL TRANSFORMATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; DEACETYLATION; GENE OVEREXPRESSION; GENE REPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; POKEMON GENE; PRIORITY JOURNAL; PROTO ONCOGENE; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE; ZBTB7 GENE;

ANIMALS; APOPTOSIS; CELL AGING; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA-BINDING PROTEINS; DOWN-REGULATION; FIBROBLASTS; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NEOPLASMS; PROTO-ONCOGENES; REPRESSOR PROTEINS; SUBSTRATE SPECIFICITY; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P14ARF;

ANIMALIA; MUS MUSCULUS;

EID: 12744269233     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature03203     Document Type: Article

References (49)

1. Lin, R. J. et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391, 811-814 (1998).
2. Melnick, A. et al. Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with compressors. Mol. Cell. Biol. 22, 1804-1818 (2002).
3. Barna, M., Hawe, N., Niswander, L. & Pandolfi, P. P. Plzf regulates limb and axial skeletal patterning. Nature Genet. 25, 166-172 (2000).
4. Ye, B. H. et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nature Genet. 16, 161-170 (1997).
5. Adhikary, S, et al. Miz1 is required for early embryonic development during gastrulation. Mol. Cell Biol. 23, 7648-7657 (2003).
6. Carter, M. G. et al. Mice deficient in the candidate tumor suppressor gene Hic1 exhibit developmental defects of structures affected in the Miller-Dicker syndrome. Hum. Mol. Genet. 9, 413-419 (2000).
7. Chen, W. Y. et al. Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nature Genet. 33, 197-202 (2003).
8. Chen, Z. et al. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to avariant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J. 12, 1161-1167 (1993).
9. Ye, B. H. et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 262, 747-750 (1993).
10. Davies, J. M. et al. Novel BTB/POZ domain zinc-finger protein, LRF, is a potential target of the LAZ-3/BCL-6 oncogene. Oncogene 18, 365-375 (1999).
11. Kukita, A. et al. Osteoclast-derived zinc finger (OCZF) protein with POZ domain, a possible transcriptional repressor, is involved in osteoclastogenesis. Blood 94, 1987-1997 (1999).
12. Pessler, F., Pendergrast, P. S. & Hernandez, N. Purification and characterization of FBI-1, a cellular factor that binds to the human immunodeficiency virus type 1 inducer of short transcripts. Mol. Cell. Biol. 17, 3786-3798 (1997).
13. Weinberg, R. A. The cat and mouse games that genes, viruses, and cells play. Cell 88, 573-575 (1997).
14. Zindy, F. et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12, 2424-2433 (1998).
15. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602 (1997).
16. Evan, G. I. et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69, 119-128 (1992).
17. de Stanchina, E. et al. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev. 12, 2434-2442 (1998).
18. Wright, W. E., Binder, M. & Funk, W. Cyclic amplification and selection of targets (CASTing) for the myogenin consensus binding site. Mol. Cell. Biol. 11, 4104-4110 (1991).
19. ARF links the tumour suppressors RB and p53. Nature 395, 124-125 (1998).
20. Rowland, B. D. et al. E2F transcriptional repressor complexes are critical downstream targets of p19(ARF)/p53-induced proliferate arrest. Cancer Cell 2, 55-65 (2002).
21. Jacobs, J. J. L., Kieboom, K., Marino, S., DePinho, R. A. & van Lohuizen, M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397, 164-168 (1999).
22. Jacobs, J. J. et al. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev. 13, 2678-2690 (1999).
23. Smith, K. S. et al. Bmi-1 regulation of INK4A-ARF is a downstream requirement for transformation of hematopoietic progenitors by E2a-Pbx1. Mol. Cell 12, 393-400 (2003).
24. Kranc, K. R. et al. Transcriptional coactivator Cited2 induces Bmi1 and MeI18 and controls fibroblast proliferation via Ink4a/ARF. Mol. Cell. Biol. 23, 7658-7666 (2003).
25. Kim, J. H. et al. The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett. 203, 217-224 (2004).
26. Vonlanthen, S. et al. The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br. J. Cancer 84, 1372-1376 (2001).
27. Jacobs, J. I. et al. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nature Genet 26, 291-299 (2000).
28. Lingbeek, M. E., Jacobs, J. J. & van Lohuizen, M. The T-box repressors TBX2 and TBX3 specifically regulate the tumor suppressor gene pHARF via a variant T-site in the initiator. J. Biol. Chem. 277, 26120-26127 (2002).
29. Brummelkamp, T. R. et al. TBX-3, the gene mutated in Ulnar-Mammary Syndrome, is a negative regulator of p19ARF and inhibits senescence. J. Biol. Chem. 277, 6567-6572 (2002).
30. Inoue, K., Roussel, M. F. & Sherr, C. J. Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1. Proc. Natl Acad. Sci. USA 96, 3993-3998 (1999).
31. Quelle, D. E., Zindy, F., Ashmun, R. A. & Sherr, C. J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83, 993-1000 (1995).
32. Sherr, C. J. & McCormick, F. The RB and p53 pathways in cancer. Cancer Cell 2, 103-112 (2002).
33. Lowe, S. W. & Sherr, C. J. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr. Opin. Genet. Dev. 13, 77-83 (2003).
34. Dimri, G. P. et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363-9367 (1995).
35. Iritani, B. M., Forbush, K. A., Farrar, M. A. & Perlmutter, R. M. Control of B cell development by Ras-mediated activation of Raf. EMBO J. 16, 7019-7031 (1997).
36. Morse, H. C. III et al. Bethesda proposals for classification of lymphoid neoplasms in mice. Blood 100, 246-258 (2002).
37. Donlon, J. A., Jaffe, E. S. & Braylan, R. C. Terminal deoxynucleotidyl transferase activity in malignant lymphomas. N. Engl. J. Med. 297, 461-464 (1977).
38. Jaffe, E. S., Harris, N. L., Stein, H. & Vardiman, J. W. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues (IARC Press, Lyon, France, 2001).
39. Whitehurst, C. E., Chattopadhyay, S. & Chen, J. Control of V(D)J recombinational accessibility of the D beta 1 gene segment at the TCR beta locus by a germline promoter. Immunity 10, 313-322 (1999).
40. Gurrieri, C. et al. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J. Natl Cancer Inst. 96, 269-279 (2004).
41. Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503-511 (2000).
42. Rosenwald, A. et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 1937-1947 (2002).
43. Hans, C. P. et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103, 275-282 (2004).
44. ARF-p53 signaling. Genes Dev. 16, 681-686 (2002).
45. Lossos, I. S. et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N. Engl J. Med. 350, 1828-1837 (2004).
46. Sanchez-Beato, M., Sanchez-Aguilera, A. & Piris, M. A. Cell cycle deregulation in B-cell lymphomas. Blood 101, 1220-1235 (2003).
47. Phan, R. T. & Dalla-Favera, R. The BCL6 proto-oncogene suppresses p53 expression in germinal-center B cells. Nature 432, 635-639 (2004).
48. Carnero, A., Hudson, J. D., Price, C. M. & Beach, D. H. p16INK4A and p19ARF act in overlapping pathways in cellular immortalization. Nature Cell Biol. 2, 148-155 (2000).
49. Hedvat, C. V. et al. Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum. Pathol. 33, 968-974 (2002).